FOLR1 and neoplasm: In this regard, the use of radiopharmaceuticals that can specifically bind to the FRα offer a reliable identification and visualization of disseminated FRα-positive tumor lesions through positron emission tomography (PET) and single-photon emission computed tomography (SPECT).